Exclusivity For Fixed-Dose Combos Going Back To The Future?
This article was originally published in The Pink Sheet Daily
Executive Summary
Ferring sues FDA to get five years of NCE exclusivity for Prepopik, and while FDA usually gets a great deal of judicial deference, Ferring may actually have precedent on its side.
You may also be interested in...
Ferring Wins In Combo Exclusivity Case; FDA Lacks 'Legitimate Reason' To Reject
Court finds FDA erred in not giving the fixed-dose combo product Prepopik five years of market exclusivity since it had awarded the exclusivity to similarly situated single-entity drug products.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.